Glucocorticoid-Induced Osteoporosis (GIOP) is a form of secondary osteoporosis caused by the chronic use of glucocorticoid medications, such as cortisone and prednisone, commonly prescribed for conditions like rheumatoid arthritis, asthma, and inflammatory disorders. Prolonged use of these medications is associated with an increased risk of bone loss and fractures. Glucocorticoids impact bone health by inhibiting bone formation, promoting bone resorption, and inducing apoptosis of osteoblasts, the cells responsible for bone formation. This imbalance leads to decreased bone mineral density and compromised bone strength. Preventive measures for GIOP include calcium and vitamin D supplementation, lifestyle modifications, and weight-bearing exercises. Bisphosphonates and other osteoporosis medications may be prescribed to mitigate bone loss in individuals at risk. Managing GIOP involves a multidisciplinary approach, with collaboration between rheumatologists, endocrinologists, and orthopaedic specialists. Regular monitoring, including bone density assessments, is crucial to identify and address bone health concerns in individuals receiving chronic glucocorticoid therapy.
Title : Knotless suture repair for chronic lateral ankle instability: A systematic review & single- arm meta-analysis
Hussein Jaber, University of Cambridge, United Kingdom
Title : The UK profemur recall and implant cobaltism
Stephen S Tower, University of Alaska Anchorage, United States
Title : The tomographic phenotype and the genotype of wormain bones
Ali Al Kaissi, National Ilizarov Medical Research Center for Traumatology and Orthopaedics, Russian Federation
Title : Total Knee Arthroplasty (TKA) in hemophilic arthropathy: Modern outcomes and perioperative strategies
Jack Russek, Touro University California, United States
Title : Musculoskeletal and orthopedic implications of Gender-Affirming Hormone Therapy (GAHT): A PRISMA-Guided systematic narrative review
Jack Russek, Touro University California, United States